Research programme: phosphodiesterase IVB inhibitors - Pfizer
Alternative Names: PDE4B inhibitors - Pfizer; Phosphodiesterase 4B inhibitors - PfizerLatest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychotic disorders; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Psychotic-disorders in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
- 04 Aug 2009 Programme is still in development with Pfizer in the US